Join the club for FREE to access the whole archive and other member benefits.


Biopharmaceutical company developing therapeutics for aging-related diseases.

resTORbio, Inc. (NASDAQ:TORC) is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for the treatment of aging-related diseases.

The decline in immune function that occurs during aging, or immunosenescence, increases susceptibility to a variety of diseases that significantly contribute to morbidity and mortality in the elderly. resTORbio’s lead program has demonstrated in several clinical trials, including a randomized, placebo-controlled trial, the potential to treat multiple diseases of aging for which there are no approved therapies. resTORbio's approach focuses on the mechanistic target of rapamycin (mTOR) pathway, an evolutionarily conserved pathway that regulates aging, and specifically on selective inhibition of the target of rapamycin complex 1, or TORC1.

Visit website:



Details last updated 03-Jan-2020

People at resTORbio

Chen Schor

Founder, President, CEO, Secretary & Director, resTORbio, Inc.

resTORbio News

mTOR inhibitors reversed immune ageing to treat viral infections in older adults (LEAF) - 21-May-2021

Much needed approach to improve immune function during the COVID pandemic


Super summary of 3rd Annual Longevity Therapeutics Summit (LEAF) - 16-Feb-2021

More and more companies making greater and greater progress - 2021 could be an exciting year


Adicet merges with resTorbio for CAR T-cell therapy pipeline funding

FierceBiotech - 30-Apr-2020

The deal moves company forward to initiating phase 1 trials in non-Hodgkin lymphoma next year


Longevity Leaders' latest report on how longevity is disrupting the world

Longevity Leaders (LSX) - 01-Jan-2020

An interesting collection of interviews and white-papers with industry leaders


resTORbio Agrees Phase 3 Human Trials with FDA (LEAF) - 19-Mar-2019

If successful, drug could be available in next few years


Is This the Anti-Aging Pill We’ve All Been Waiting For?

MIT Technology Review - 28-Mar-2017

Novartis sought to see whether giving low doses of everolimus to people over 65 increased their r...

Topics mentioned on this page:
Laboratory Automation, Immunotherapy